Journal of Psychiatry

Efficacy of Antipsychotic Medications in Schizophrenia

Luxian Lana^* Department of Psychiatry, Yonsei University, Seoul, South Korea
^*Correspondence: Luxian Lana, Department of Psychiatry, Yonsei University, Seoul, South Korea, Email:

Received: 03-Jul-2023, Manuscript No. JOP-23-19823; Editor assigned: 06-Jul-2023, Pre QC No. JOP-23-19823 (PQ); Reviewed: 20-Jul-2023, QC No. JOP-23-19823; Revised: 27-Jul-2023, Manuscript No. JOP-23-19823 (R); Published: 03-Aug-2023, DOI: 10.35248/2378-5756.23.26.609

Introduction

Schizophrenia is a severe mental disorder that affects approximately 1% of the global population. It is characterized by a range of symptoms, including delusions, hallucinations, disordered thinking, and abnormal behavior. Antipsychotic medications are the primary treatment for schizophrenia, and they have been shown to be effective in reducing the severity of symptoms.

Antipsychotic medications work by blocking dopamine receptors in the brain. Dopamine is a neurotransmitter that regulates mood, motivation, and other cognitive functions [1]. In people with schizophrenia, there is an over activity of dopamine in certain areas of the brain, leading to the symptoms of the disorder. Antipsychotics work by blocking the receptors, reducing the over activity and improving the symptoms.

There are two types of antipsychotics: Typical and atypical. Typical antipsychotics were the first type of antipsychotics developed, and they work by blocking dopamine receptors. Some examples of typical antipsychotics include chlorpromazine, haloperidol, and fluphenazine. Atypical antipsychotics, on the other hand, are a newer generation of antipsychotics that work by blocking both dopamine and serotonin receptors [2]. Some examples of atypical antipsychotics include olanzapine, risperidone, and quetiapine.

Description

Studies have shown that both typical and atypical antipsychotics are effective in reducing the symptoms of schizophrenia. In general, atypical antipsychotics are more effective than typical antipsychotics, but they are also more expensive and have a higher risk of side effects [3]. The choice of antipsychotic medication depends on the individual patient and the severity of their symptoms.

In addition to reducing the symptoms of schizophrenia, antipsychotics can also help prevent relapses. Studies have shown that patients who take antipsychotics are less likely to experience a relapse of their symptoms than patients who do not take antipsychotics [4]. However, it is important to note that antipsychotics are not a cure for schizophrenia, and patients may still experience symptoms even while taking the medication.

Despite the efficacy of antipsychotics in treating schizophrenia, they are not without side effects. Common side effects of antipsychotics include drowsiness, weight gain, and tremors. Some atypical antipsychotics can also cause metabolic side effects, such as increased cholesterol levels and diabetes. Additionally, long-term use of antipsychotics can lead to tardive dyskinesia, a movement disorder characterized by repetitive, involuntary movements [5].

One of the challenges in treating schizophrenia with antipsychotics is ensuring that patients take the medication as prescribed [6]. Nonadherence to antipsychotic medication is common in patients with schizophrenia, and it is a major factor in the relapse of symptoms. Strategies to improve medication adherence include educating patients about the importance of taking their medication, setting up a reminder system, and involving family members in the treatment process.

Conclusion

In conclusion, antipsychotics are an effective treatment for schizophrenia, and they can help reduce the severity of symptoms and prevent relapses. However, they are not without side effects, and it is important to monitor patients closely while they are taking the medication. Patients and their families should also be aware of the importance of taking antipsychotics as prescribed and the potential consequences of nonadherence. Despite the challenges, antipsychotics remain an essential part of the treatment plan for patients with schizophrenia.

References

1. Rodrigo A, Wijesinghe C, Kuruppuarachchi KA. Changes in attitudes toward psychiatry with introduction of a new curriculum: Experiences of a Sri Lanka medical school. SL J Psychiatry. 2012;3(1):14-16.

   [Google Scholar]

2. Lyons Z, Janca A. Impact of a psychiatry clerkship on stigma, attitudes towards psychiatry, and psychiatry as a career choice. BMC Med Educ. 2015;15:34.

   [Crossref] [Google Scholar] [PubMed]

3. Feifel D, Moutier CY, Swerdlow NR. Attitudes toward psychiatry as a prospective career among students entering medical school. Am J Psychiatry. 1999;156(9):1397-1402.

   [Crossref] [Google Scholar] [PubMed]

4. Sarker MR, Khan MZR, Jahan N, Maruf MM, Chowdhury MW, Hamid MA, et al. Attitudes towards psychiatry among undergraduate medical students. Bang J Psychiatry. 2017;28(2):45-49.

   [Crossref] [Google Scholar]

5. Goldenberg MN, Williams DK, Spollen JJ. Stability of and factors related to medical student specialty choice of psychiatry. Am J Psychiatry. 2017;174(9):859-866.

   [Crossref] [Google Scholar] [PubMed]

6. Kang PS, Kim SBG, Kang YA. Specialty preference of the premedical school students in Taegu city. Korean J Med Educ. 2000;12(2):215-226.

   [Crossref] [Google Scholar]